Xinzhi Bio has successfully met, and the research and development capabilities in the industry need to be strengthened

Fengkou Finance reporter Xu Yaowen

In the second half of this year, the rhythm of the Northern Stock Exchange accelerated significantly. Following the "5" of the Beijing Stock Exchange last week, only one company in the Beibei Stock Exchange was attended this week.

On August 10, the official website of the Bei Stock Exchange announced that Ningbo Xinzhi Biotechnology Co., Ltd. (hereinafter referred to as "Xinzhi Biological") was publicly issued and applied for the listing committee of the Bei Stock Exchange. Public information shows that Xinzhi Bio is publicly issued and listed this time, and the sponsor is CITIC Securities.

Xinzhi Biological is located in Ningbo City, Zhejiang Province. It was established in 2001. It is a high -tech enterprise specializing in users and equipment specializing in the field of life science research and industrialization.

In 2014, Xinzhi Bio was listed on the New Third Board. In 2021, the company was identified as a national "specialized new" enterprise. On June 15 this year, the application for the public issuance and listing of Xinzhi Bio's publicly issued and listed on the Beijing Stock Exchange was accepted; on August 11, Xinzhi Bio was successfully passed by the Municipal Party Committee of the Bei Stock Exchange.

Flush iFind data shows that the company's operating income and profits in the past four years have generally shown an upward trend. Especially in 2021, the company's net profit attributable to mothers increased by 31.65%year -on -year.

Speed ​​speed of the Beijing Stock Exchange does not mean that it will relax the review requirements for enterprises. The review opinions of Xinzhi Biological show that the Municipal Party Committee of the Peking Exchange specially requires Xinzhi Biological supplementation in detail about sales models, gross margins, and technical advanced. In addition, the committee proposes relevant review opinions in terms of the rationality of the sales model and gross profit margin, the actual controller, the high amount of withdrawal of the directors and supervisors, and the rationality and compliance of funds.

In terms of technological advanced nature, the prospectus of Xinzhi Biological shows that the company has long adhered to independent innovation and continued to maintain high R & D investment to maintain core competitive advantages. As of December 31, 2021, the company has obtained 62 authorized patent technologies, including 15 invention patents, 41 practical new patents, and 6 exterior design patents.

From 2019 to 2021, the research and development cost rates of Xinzhi Bio were 8.67%, 8.80%, and 7.45%, respectively. This level can be ranked among the listed companies listed by the Beijing Stock Exchange, but from the perspective of the industry, Xinzhi's Xinzhi Biological has not yet formed an advantage.

The prospectus shows that the main hands of Xinzhi Biological in the industry include Taylin Biology, Ribbestco, Sande Technology and Hexin Instruments. From 2019 to 2021, the company's R & D expense rate was slightly higher than Ribbestco in 2019 and 2020, and lower than the industry average.

R & D expense ratio and comparison company comparison situation

At present, foreign superior companies in the instrument industry still have technical advantages and occupy a high market share. The company needs to continuously improve the technical level and service capabilities to further develop the market.

This time, the new Zhel biological investment intends to overcome the difficulty of manufacturing technology, optimize the manufacturing process, further improve the company's product system, maintain the company's technical strength and continue to invest in R & D investment.

The prospectus information shows that without considering the excessive sale option, the company plans to publicize the shares of not less than 22.19 million shares, raising a total of about 441 million yuan for the industrialization construction project of life science instruments and research and development center construction projects. , Construction of technical services and marketing network construction projects and supplementation of mobile funds.

- END -